NRx Pharmaceuticals Transitions to Commercial Stage Following FDA Approval of Preservative-Free Ketamine

NRx Pharmaceuticals (NRXP) has officially transitioned from a development-stage company to a commercial pharmaceutical entity following the FDA approval of its preservative-free ketamine. The company has already received its initial order and is targeting a significant share of an estimated $400 million annual market, which is currently expanding at a rate of 17% per year. Financially, NRx ended the quarter with approximately $19.8 million in cash, bolstered by a recent $22 million gross public offering. Management intends to fund future operations through product revenue, clinic income, and strategic use of its at-the-market facility to minimize shareholder dilution. Looking ahead, the company aims to submit a rolling NDA for NRX-100 by year-end, with potential approval expected in 2027.

Seeking Alpha ·

NRx Pharmaceuticals Transitions to Commercial Stage Following FDA Approval of Preservative-Free Ketamine

Tickers: $NRXP

Topics: Cash Runway Commercialization FDA Approval Product Pipeline

Read the full article at Seeking Alpha

More World news